



## ASX Announcement

### Phase II Bisantrene trial data to be presented at ASH 2020

- Phase II Bisantrene clinical trial data to be presented at the American Society for Haematology 2020 Annual Conference (ASH 2020)
- All ASH presentations are selected by peer-review
- ASH is the premier international conference for haematology

**5 November 2020** – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel's Sheba Medical Centre has been accepted for presentation at the *American Society for Haematology 2020 Conference* (ASH 2020).

This open label, single agent trial, led by Professor Arnon Nagler, studied patients (n=10) with relapsed or refractory Acute Myeloid Leukaemia (R/R AML) who on average had failed three prior lines of treatment. Bisantrene was found to be well tolerated, and after only a single course of treatment, had an overall clinical response rate of 40% (ASX Announcement: June 16 2020).

The ASH Annual Meeting is the premier international clinical conference for malignant and non-malignant haematology and attracts over 30,000 attendees across four days. The annual meeting presentations are chosen by peer-review and cover the latest developments in scientific and clinical research in the field of haematology.

The presentation, entitled "*A Phase II Study of Bisantrene in Patients with Relapsed/ Refractory Acute Myeloid Leukemia*" will be presented on 5 December 2020. The abstract for this presentation is available via:

[ash.confex.com/ash/2020/webprogram/Paper135947.html](http://ash.confex.com/ash/2020/webprogram/Paper135947.html)

**- ENDS -**

#### About Race Oncology (RAC: ASX)

Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML) as well as breast and ovarian cancer. RAC is pursuing an exciting '5-Path' clinical development strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with clinical trials to begin in 2020.

Release authorised by:

Phil Lynch, CEO/MD

[phillip.lynch@raceoncology.com](mailto:phillip.lynch@raceoncology.com)

Media contact:

Jane Lowe, IR Department

+ 61 411 117 774

[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)